Rob is a Senior Advisor on the Frazier Life Sciences team with over 25 years of experience as a physician, entrepreneur, and immuno-oncology expert.
Rob joined Frazier Healthcare Partners' Life Sciences team in 2015 as a Senior Advisor, and has been working with Frazier and Frazier-backed portfolio companies as an entrepreneur and executive for over 13 years. Currently, he is President and CEO of VentiRx Pharmaceuticals, a Frazier-backed company which is developing a small molecule therapeutic to activate the immune system against solid tumors. He co-founded VentiRx while an entrepreneur-in-residence at Frazier, and has led the company through its transformational partnership with Celgene. He also currently leads Celgene’s immuno-oncology research and development efforts and is helping build Celgene’s Immuno-Oncology Center of Excellence in Seattle.
Prior to VentiRx, Rob served as Senior Vice President and CMO of Dendreon Corporation and led clinical development of Provenge which was approved for metastatic prostate cancer. Before Dendreon, he was Vice President of Medical Genetics at Corixa, a Frazier-backed company which was acquired by GlaxoSmithKline. Earlier, Rob was an Assistant Professor at Harvard Medical School and an Associate Physician at Brigham and Women’s Hospital in Boston.
Rob currently serves on the boards of NanoString Technologies (NASDAQ: NSTG), Adaptive Biotechnologies, and VentiRx.
Rob holds an M.D. from UCLA and a Ph.D. in Biology from the Salk Institute. He is clinically-boarded in Medical Genetics, and currently holds clinical and research faculty positions at the University of Washington School of Medicine.
University of California, Los Angeles (M.D.)
Salk Institute (Ph.D.)